FDA has approved Cervista High Throughput Automation (HTA), a cervical cancer screening kit from Hologic. Hologic is a manufacturer and supplier of premium diagnostic and surgical products and medical imaging systems that specifically cater to the medical needs of women. The Cervista HTA is to be used along with Hologic’s Cervista human papillomanvirus (HPV) HR test.
Cervista Testing Kit
The proprietary Invader technology from Hologic has been incorporated in the HPV HR test, which is used for detecting 14 high risk types of HPV linked with cervical cancer and precancerous lesions. The new Cervista HTA performs DNA extraction and detection automatically during the Cervista HPV HR test. The combination of the two systems for screening cervical cancer requires a simple loading of the instrument with the samples at one go and get to see the results the next day. After the FDA approval of the Cervista HTA, Hologic is able to provide the most comprehensive package for cervical screening. The human papillomavirus is indicative of cervical cancer in humans, which is next to breast cancer amongst the cancer affecting women worldwide.
Hologic has been involved in developing screening mechanisms for cervical cancer since 1986 when they started with the ThinPrep Pap test. This test is one of the most widely used ones in the US and many other countries. Hologic later came up with ThinPrep Imaging Systems and Cervista HTA, which together form a complete package for cervical cancer screening. The Cervista HTA is capable of processing multiple sample batch sizes for mid-volume laboratories. The other popularly used cervical screening test from Hologic is the Cervista HPV 16/18 test, which covers all the testing procedures for the entire range of cervical cancer screening.